You don’t hear about special purpose acquisition company (SPAC) mergers too much these days, but Medera is set to change that as the cardiovascular-disease-focused biotech dusts off this lesser-used pathway to the public markets.
Eli Lilly has vaulted into an AI-enabled drug discovery deal, partnering with RNA specialist Genetic Leap in a pact worth up to $409 million in upfront and milestone payments.
Just a few months after dosing the first patient in a phase 2 trial for newly diagnosed glioblastoma, IN8bio is hitting the brakes—and laying off half of its workforce.
The proposed $24.6 billion merger between supermarket giants Kroger and Albertsons floundered on Tuesday after judges overseeing two separate cases both halted the deal
Alaska Airlines says it will launch service from Seattle to Tokyo and Seoul next year as part of a plan to boost international flying in the next several years
The Biden administration has given approval for the sale of oil and gas leases in Alaska, leaving the door open for drilling in a portion of the pristine Arctic National Wildlife Refuge
U.S. stock indexes drifted lower in the runup to the highlight of the week for the market, the latest update on inflation
Parexel, a global contract research organization headquartered in Durham, North Carolina, is beefing up its ability to gather real-world data by bringing Mike D’Ambrosio on board as senior vice president and global head of real world research.
Abbott has launched a pivotal clinical trial to see if its deep-brain stimulation approach can make headway against treatment-resistant depression.
A new type of mpox, clade Ib, has been spreading rapidly within the Democratic Republic of Congo and leaking outside the African nation’s borders since Sept. 2023. In response, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern (PHEIC) last month, the second such declaration for an mpox variant in the past two years.
Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
Pfizer sees weight gain in cancer patients, aims to enter phase 3 in 2025
‘Cooking with gas’: Regeneron sees its Opdualag rival as next big thing for treating solid tumors
IO Biotech’s vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial
iTeos-GSK’s TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
Eli Lilly sells Life Sciences Studio lab to Arctoris, moving automation platform from San Diego to Oxford
Biolexis enters oral GLP-1 horse race with preclinical study showing small molecule reduced weight of obese mice
AstraZeneca steps out from Daiichi’s shadow, posting data on ADC rivals to AbbVie, Pfizer
Wall Street Rises to Turn a Dismal Week Into Just a Bad One
Tesla Recalling Almost 700,000 Vehicles Due to Tire Pressure Monitoring System Issue
